MILITARY SCIENTIST 

DIED 

MYSTERIOUSLY 

AFTER FILING COVID VACCINE PATENT

By

Søren Nielsen

2021

 As we move further down the rabbit hole of exactly what in the devil has been going on in China’s "bat labs", we now turn our attention to one Zhou Yusen – a Chinese military scientist specializing in coronaviruseswho collaborated with the Wuhan Institute of Virology’s "Bat Woman", Zhengli Shi – with at least one project to geneticially manipulate coronaviruses having been funded by three grants from the National Institutes of Heath (NIH)  – home to Dr. Anthony Fauci – via US universities, according to documents obtained by The Weekend Australian (ostensibly leaked by Aussie intelligence). 

The previously undisclosed NIH funding of a PLA military scientist is separate from millions in grants awarded EcoHealth alliance, which also collaborated with the WIV.

The revelation shows American money was funding risky ­research on coronaviruses with People’s Liberation Army scientists – including decorated military scientist Zhou Yusen and the Wuhan Institute of Virology’s "Bat Woman", Shi Zhengli.

Now we learn that Zhou, 54, is dead – three months after filing a patent for a COVID-19 vaccine in Feb. 2020.

According to the report, Zhou’s May 2020 death went largely under the radar, despite the fact that he was an award-winning scientist at the PLA’s Laboratory of Infection and Immunity at the Beijing Institute of Microbiology and Epidemiology. 

There were no reports paying tribute to his life. 

His death was only mentioned in passing in a Chinese-media report in July and at the end of a December scientific paper. 

Both had the word ­"deceased" in brackets after his name.

And while Zhou’s death may have been suspicious (or he may have simply died of COVID), the revelation that the US government was funding his research with the WIV may provide a clue as to why US officials – Dr. Fauci (backed by the "scientific community" after his lapdog, EcoHelath Alliance’s Peter Daszak, penned a "natural origin or you’re a lunatic" letter in the Lancet) – peddled the CCP’s "natural origin" theory, while any suggestion that it could have been created in and/or leaked from the very lab which received NIH dollars was strictly verboten.

US paid Chinese People`s Liberation Army to engineer Coronaviruses.

Emails released under a Freedom of Information request from Buzzfeed this week showed that, in the early days of the pandemic, Dr Fauci was concerned that US funding had gone towards gain-of-function research in China.

In other emails, scientists wrote to Dr Fauci expressing the preliminary view that the SARS-CoV-2 genome appeared "inconsistent with expectations from evolutionary theory" and that it had some features that "potentially look engineered".

In short, "conflict of interest" doesn’t even begin to explain what Fauci is now going to have to explain the next time Rand Paul has him in the hot seat.

The revelation shows American money was funding risky ­research on coronaviruses with People’s Liberation Army scientists – including decorated military scientist Zhou Yusen and the Wuhan Institute of Virology’s "Bat Woman", Shi Zhengli.

National security sources said the ties between Zhou and Dr Shi ­supported claims by US intelligence that the Wuhan Institute of Virology was engaged in "secret military activity."

How long was China sitting on the genetic sequence for SARS-CoV-2?

If we’re considering the timeline and its implications, Zhou died three months after filing a Feb. 24, 2020 patent application for a COVID-19 vaccine. 

While this could mean that he was working on a COVID-19 vaccine before the virus became public knowledge in December 2019, keep in mind that Moderna was able to design the sequence for their COVID-19 vaccine just two days after Chinese officials released its genetic sequence on Jan. 11, 2020 – filing for their first related patent in March, two months later.

Also note that Zhou had been working on coronavirus vaccines since at least 2006 in response the original SARS-CoV outbreak – authoring a study which found that "the vaccines containing the (receptor-binding domain) of SARS-CoV S protein may induce sufficient neutralising antibodies and long-term ­protective immunity against SARS-CoV challenge in the ­established mouse model."

So, assuming an expert would need approximately two months to go from genomic sequence to patent application, it implies that China withheld the genetic sequence for a month before its Jan. 11 public release. 

Or, Zhou may have had more of a "head start" than that. 

"This is something we have never seen achieved before, raising the question of whether this work may have started much ­earlier," said Nikolai Petrovsky from Flinders University.

(And if one wants to explore the implications assuming SARS-CoV-2 was genetically engineered, Karl Denninger has some thoughts below)

And while we may never know the full extent of Zhou’s role in all of this, he and "bat woman" Zhengli were working on a COVID vaccine right before the pandemic.

Right before the pandemic, Zhou and three other scientists from the PLA-run Beijing Institute of Microbiology and Epidemiology – Yuehong Chen, Lei He and Shishui Sun – partnered with two Wuhan Institute of Virology scientists – Dr Shi and Jing Chen – and eight Chinese scientists now based in the US at the University of Minnesota and the Lindsley Kimball Research Institute, New York Blood Centre. 

Their paper, titled Molecular Mechanism for Antibody-­Dependent Enhancement of Coronavirus Entry, was submitted to the Journal of Virology on November 27, 2019, and was published on February 14, 2020.

The research examined MERS and SARS coronaviruses as avenues for antibody-based ­antiviral drug therapy to treat coronaviruses.

Their paper had some positive results: 

"Taken together, our ­results show that RBD-specific neutralising MAbs bind to the same region on coronavirus spikes as viral receptors do, trigger conformational changes of the spikes as viral receptors do, and mediate ADE through the same pathways as viral-receptor-dependent viral entry."

They found this "novel molecular mechanism for antibody-enhanced viral entry" could "guide future vaccination and ­antiviral strategies".

This study was conducted "in vitro", meaning in a petri dish or test tube, using humanised kidney and lung cells. 

Their last paragraph indicated the next step in a future paper would be to conduct "in vivo" experiments with ­humanised mice or primates. 

A paper published in Nature ­Reviews Immunology 18 months later, in April this year, would find that "neutralising monoclonal antibodies" could help the treatment of Covid-19.